Promising Phase I Correlative SENTI-202 Data is Consistent with Clinical Activity & Unique Logic Gated Mechanism of Action
- Will present clinical data consistent with SENTI-202 mechanism of action, including:
- CD33 OR FLT3 logic gated CAR approach for targeting both AML blasts and leukemic stem cell NOT EMCN logic gated inhibitory CAR approach for protection of hematopoietic stem and progenitor cells
- Supporting data for SENTI-202 PK, patient disease characterization, and patient responses